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Lars Oddershede has an interdisciplinary education from Aalborg University, 
Denmark. He studied for a Bachelor’s degree in Medicine with an Industrial 
Specialization, which includes courses in physiology, pathophysiology, anatomy, 
pharmacology, and clinical placements at local hospitals. In 2011, he finished his 
Master’s degree in Medical Market Access. During this two year course he 
primarily focused on Health Economics with a special emphasis on applied cost-
effectiveness analysis of medical devices. A wish to gain a greater insight into the 
commercial perspective motivated him to do a separate degree in Business 
Administration next to his PhD studies. After completing his degree in Business 
Administration in 2013 he started working part-time as a biostatistician at Aalborg 
University Hospital.  
Throughout his research-career, Lars has been especially interested in the 
application of statistical methods. In acknowledgement that good quantitative 
methods are merely useful if the data informing the analysis are equally good, his 
PhD studies focused on how to get optimal estimates of an intervention’s 
effectiveness under non-ideal circumstances.  
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FOREWORD 
If you had told me that one day I would be handing in my PhD thesis in Health 
Economics during my years as an undergraduate student in Medicine, chances are I 
would have laughed. Although, I am not sure that my dad would have disputed it.  
But things changed when I started my graduate studies in Medical Market 
Access. Here, Lars Ehlers sparked my interest for Health Economics and for 
research. During this period I published my first two articles in cooperation with 
Lars Ehlers. Having tasted blood, I wanted more. With a great sense of gratitude I 
accepted Lars Ehlers’ offer to become a PhD student.  
During my time as a PhD student countless people have helped me and for 
that I am grateful. I owe a special thanks to Jan Jesper Andreasen, Lars Ehlers, and 
Karin Dam Petersen for supervising me throughout the process. Karin, thank you so 
much for agreeing to help me when the focus of my research shifted towards your 
field of expertise.  
In addition, special thanks are extended to my co-authors and those who 
are acknowledged in my papers. Your valuable comments and corrections have 
been most appreciated.  
Also, I am grateful to Mark Sculpher for giving me the opportunity to visit 
the Centre for Health Economics at University of York. Working alongside you and 
Simon Walker has been the biggest learning opportunity of my PhD.  
On that note, I would like to thank my girlfriend Tessa Bay for her 
patience. Patience when I suddenly decided I was going to spend five months in the 
UK. Patience when I spent long hours at the office or in front of the computer at 
home. And patience when my work-related frustrations left the office along with 
me and came home to you. 
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Sabrina Storgaard Sørensen: thank you for all the chats and for your 
advice. Every PhD student should have as great an office-buddy as you. To the rest 
of my wonderful colleagues in the Danish Center for Healthcare Improvements: 
thank you for the discussions and your feedback on my written work. 
Last but not least, I want to thank my friend and mentor Søren Lundbye-
Christensen. Thank you for having faith in me and for saying the words I will never 
forget you for: “The first author is merely the useful idiot with a Word document - 
the real genius is the last author. Someday, Lars, you will also be the last author and 
be able to do real research”. I sure hope so! 
 
I alone am responsible for the final content and any mistakes in the thesis. 
 
Lars Oddershede,  
Aalborg, September 2014. 
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RESUME IN ENGLISH  
Resources are scare and healthcare systems must, therefore, prioritize which new 
technologies should be funded, and which should be rejected. To aid decision 
makers in their choice, economic evaluations can be conducted to assess the cost-
effectiveness of the new technologies. However, the Danish guideline for economic 
evaluations has no stated preference for the type of economic evaluation and 
thereby no preference for how effectiveness should be measured. 
The present thesis argues that two problems could be solved by updating 
the Danish guideline for economic evaluations to include a stated preference for 
measuring effectiveness in terms of quality adjusted life-years (QALYs). Firstly, it 
would be possible to compare the cost-effectiveness of new technologies across 
conditions. Secondly, it would make it possible to capture both effects and side 
effects of new technologies in a single outcome-measure. Therefore, the present 
thesis explores how to procure optimal estimates of quality of life, i.e. utility, for 
QALY calculations in different situations, where different data are available. 
It is discussed how to procure utility estimates in three situations where 
different data are available to the analysts. Firstly, the situation where individual 
patient-level data (IPD) on utility are available from the preferred generic 
preference-based measured of health, assumed to be the three level version of the 
EuroQol five dimensions of health questionnaire (EQ-5D). Secondly, the situation 
where IPD on EQ-5D are unavailable but foreign utilities estimates can be 
identified in the literature. Thirdly, the situation where analysts neither have IPD on 
EQ-5D profiles, nor foreign utilities of the EQ-5D, but other measures of health are 
available.  
Using the methodological papers and economic evaluations conducted 
during the PhD project; the thesis exemplifies why it is important to use 
standardized methods when calculating QALYs in economic evaluations. If the 
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Danish decision makers are to use economic evaluations as a tool for prioritizing 
between new technologies, the QALY estimates must be a reflection of the national 
preferences for health. As a result, optimal utility estimates can be obtained by 
applying the national value set to the IPD on EQ-5D profiles. However, this is not 
an option if IPD on EQ-5D profiles are unavailable. In that situation, foreign 
utilities of the EQ-5D can be used, but these cannot be applied in a Danish 
economic evaluation without adjustment. Therefore, a novel method was developed 
to adjust foreign mean utility values to make them transferable and applicable to the 
Danish setting. If both IPD on EQ-5D profiles and foreign utilities of the EQ-5D 
are missing, calculations may be standardized by mapping other measures of health 
to the EQ-5D. Mapping by statistical association provides accurate predictions of 
what the incremental QALYs would be, if EQ-5D data had been available.  
In summary, the thesis recommends that a shared measure of health, 
QALYs, is used in order to make the results of the economic evaluations submitted 
to the Danish Health and Medicines Authorities more comparable across conditions 
and interventions. An efficient use of the scarce resources could then be obtained by 
choosing to fund the new technologies which are considered cost-effective.  
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RESUME PÅ DANSK 
Da ressourcerne er begrænsede i sundhedsvæsenet skal der tages stilling til hvilke 
nye behandlinger der skal tilbydes og hvilke der skal afvises. For at hjælpe 
beslutningstagerne med deres valg kan omkostningseffektiviteten af de nye 
behandlinger undersøges ved hjælp af sundhedsøkonomiske evalueringer. 
I denne afhandling argumenteres der for, at to typiske problemer ved 
sundhedsøkonomiske evalueringer kan forhindres ved, at opdatere den danske 
guideline så den inkluderer en præference for at sundhedsgevinster opgøres i 
kvalitetsjusterede leveår (QALYs, fra det engelske quality adjusted life-years). For 
det første ville dette gøre det muligt, at sammenligne omkostningseffektiviteten af 
nye behandlinger på tværs af sygdomme og interventioner. For det andet ville det 
blive muligt, at fange både effekter og bivirkninger af nye behandlinger i ét 
effektmål. Af denne grund undersøges det i afhandlingen hvordan optimale 
estimater af livskvalitet, til QALY beregningen, kan opnås i forskellige situationer 
med forskellig data-tilgængelighed.  
Gennem brug af den metodeudvikling og de sundhedsøkonomiske 
evalueringer der er udført, som en del af ph.d. projektet, bliver det eksemplificeret 
hvorfor det er vigtigt, at anvende standardiserede metoder til at beregne QALYs i 
sundhedsøkonomiske evalueringer.  
Konklusionen på afhandlingen er, at et fælles effektmål, QALYs, bør 
beregnes på standardiseret vis og anvendes i alle sundhedsøkonomiske evalueringer 
der indsendes som en del af ansøgningen om tilskud til lægemidler hos 
Sundhedsstyrelsen.  
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IX 
PRESENTATIONS AND PUBLICATIONS 
The papers presented in Appendices A-F are the product of the PhD project. Most 
of the studies have either been accepted for presentation or for publication. A 
summary of presentations and publications is provided below:  
The paper entitled “Cost-effectiveness analysis of protease inhibitor 
monotherapy vs. ongoing triple-therapy in the long-term management of HIV 
patients” has been accepted for a poster presentation at the International Society for 
Pharmacoeconomics and Outcomes Research 17th Annual European Congress in 
Amsterdam, November 2014, and for an oral presentation at the International 
Congress on Drug Therapy in HIV Infection in Glasgow, November 2014, and is 
currently in peer review, see Appendix A.  
The paper entitled “Health economic evaluation of single-lead atrial pacing 
vs. dual-chamber pacing in sick sinus syndrome” is published in the peer reviewed 
journal Europace, see Appendix B1. 
The paper entitled “Adjusting foreign utilities of the EQ-5D-3L increases 
their transferability” is currently in peer review, see Appendix C. 
The paper entitled “Estimation of utility values from visual analog scale 
measures of health in patients undergoing cardiac surgery” is published in the peer 
reviewed journal ClinicoEconomics and Outcomes Research, see Appendix D2.  
The paper entitled “Endoscopic vein harvesting for coronary artery bypass 
grafting is safe and reduces postoperative resource consumption” was accepted for 
oral presentations at the 2014 annual meeting in the Danish Society of 
Cardiothoracic Surgery and at the 6th joint conference of the Scandinavian 
Association for Thoracic Surgery in Gothenburg, September 2014, and has been 
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accepted for publication in the peer-reviewed Journal of Cardiovascular Diseases 
& Diagnosis, see Appendix E3. 
The paper entitled “Long-term cost-effectiveness of endoscopic vs open 
vein harvest for coronary artery bypass grafting” was accepted for oral presentation 
at a discussed session at the 10th world congress in health economics organized by 
the international Health Economics Association in Dublin, July 2014, and is 
currently in peer review, see Appendix F. 
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CHAPTER 1. INTRODUCTION 
The PhD thesis which you are about to read is in the field of economic evaluation of 
health technologies. During the project period, three economic evaluations were 
performed using quality adjusted life-years (QALYs) as the measure of 
effectiveness, see appendices A, B1, and F. Carrying out these economic evaluations 
gave rise to a series of methodological considerations. All the methodological 
considerations revolved around a central theme: how could available data be used to 
obtain the best possible estimates of utility to calculate QALYs in economic 
evaluations? This thesis compiles these considerations.  
The thesis is meant as a helpful tool in the process of updating the Danish 
national guideline for economic evaluations4. Before embarking on the discussion 
about how Denmark should put the ‘Q’ in QALY, Chapter 1 will explain why 
economic evaluations of health technologies are necessary and how these may be 
carried out. 
 
1.1. WHY ECONOMIC EVALUATIONS ARE NECESSARY  
“The reason economic evaluation is needed is because markets alone do 
not provide efficient solutions, particularly in health care. However, 
when free markets don’t exist, active decisions have to be made about 
which health services should be funded given the scares resources 
available… …The overall aim is to maximize benefits given the 
resources available” 
(Fox-Rushby et al. 2005)5 
Resources, be it money, people, time, facilities, equipment, or knowledge, are 
scarce6. In the absence of a free market for health care, the government must decide 
which new health care interventions should be funded and which should be 
rejected. Randomized clinical trials are considered the golden standard for 
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providing evidence that a new technology is more efficient than the existing 
technology. However, the decision to adopt a new technology cannot merely be 
based on the evidence that it is more efficient than the existing technology as new 
technologies are frequently also more expensive than the existing. Hence, it is 
necessary to assess the value-for-money of the new technology to avoid inefficient 
use of the scarce resources. The value-for-money (cost-effectiveness) of a new 
intervention is assessed in an economic evaluation which compares the new 
intervention and its alternatives in terms of costs and consequences6. By choosing to 
fund the interventions which are deemed cost-effective, an efficient use of the 
scarce resources could be obtained6.  
It does, however, vary to what extent the economic evaluations are used in 
decision making. The UK National Health Service (NHS) has an advisory body 
called the National Institute for Health and Care Excellence (NICE) which advises 
the NHS on how to provide equitable access for all patients to the most clinically 
effective and cost-effective treatment7. To advice the NHS about how to prioritize 
the scarce resources, NICE assesses and commissions technology appraisals of both 
new and existing medicines and treatments. In contrast, economic evaluations are 
used more infrequently in the Danish healthcare system8. 
 
1.2. ECONOMIC EVALUATIONS OF NEW TREATMENTS IN 
DENMARK 
In Denmark, pharmaceutical companies have the opportunity to submit an 
economic evaluation as part of the reimbursement application for the Danish Health 
and Medicines Authorities9. As it is optional, rather than a requirement, to submit 
cost-effectiveness evidence, it is not always done. If the application contaisn an 
economic evaluation, it is sent to external validation to ensure that the Danish 
guideline for economic evaluation has been followed. Although other agencies, like 
NICE, frequently update their guideline, the Danish guideline have remained the 
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same since they were developed in 19984,10. As a result, the Danish guideline does 
not state what the preferred outcome-measure should be. Instead, the Danish 
guideline states, that no single outcome-measure can be used in all economic 
evaluations4,10. As such, the Danish guideline leaves it up to the pharmaceutical 
companies to choose which type of economic evaluation to perform. 
By leaving it up to the pharmaceutical companies to choose how the 
effectiveness of the treatment is measured, two issues arise: firstly, it becomes 
difficult to compare the results of one economic evaluation with another, and 
secondly, it could be questioned whether pharmaceutical companies always choose 
an outcome-measure which captures both the effects and the side effects of their 
new product.  
This thesis will address how these two issues may be handled by updating 
the Danish guideline to take a position towards which type of economic evaluation 
should be preferred.  
 
1.3. TYPES OF ECONOMIC EVALUATIONS  
Economic evaluations are typically divided into partial and full economic 
evaluations. Full economic evaluations assess both the costs and outcomes of two 
or more interventions for the same condition6. Comparative results are then 
presented using the incremental cost-effectiveness ratio (ICER), which shows the 
additional cost associated with obtaining an additional unit of health. The three 
types of full economic evaluations are called: cost-effectiveness analysis, cost-
utility analysis, and cost-benefit analysis. The main difference between these is the 
method for valuing health outcomes.  
The cost-benefit analysis is consistent with economic theory and provides 
the result, which the market would produce if one had been operating. This is 
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frequently referred to as the welfarist approach to economic evaluation of health 
care interventions and it entails valuing both costs and health oucomes in monetary 
units. As the current Danish guideline states that a cost-benefit analysis should only 
be submitted along with either a cost-effectiveness analysis or a cost-utility 
analysis, it is not considered likely to become the preferred type of economic 
evaluation when updating the guideline. Consequently, the cost-benefit analysis 
will not be discussed further in this thesis. 
Where welfarism relies on the premise that social welfare is a function of 
individual utility, extra-welfarism relies on the assumption that social welfare can 
be measured on other information, such as health11. The extra-welfarist would argue 
that economic evaluations should be conducted to help allocate the health care 
budget and hence the resources consumed should be compared to the health 
outcomes. As such, both cost-effectiveness analysis and cost-utility analysis are 
conducted from an extra-welfarist approach as they measure value in terms of 
health outcomes.  
In a cost-effectiveness analysis, the effectiveness is measured in a single 
clinical or health-related outcome relevant to all interventions being compared5. 
Examples of such outcome-measures could be ‘Cases detected’, ‘Life-years 
gained’, or ‘Episode-free days’6. The main limitation of the cost-effectiveness 
analysis is that it only considers a single outcome and that outcome may only be 
applicable to the interventions being compared. This causes two problems. Firstly, 
the results may not be useable for comparison across other interventions and 
disease-areas5. Secondly, by using a single outcome-measure it is impossible to 
capture both effects and side effects of a new technology.  
The cost-utility analysis offers a solution for these two issues by measuring 
the outcome in terms of quality adjusted life-years (QALYs). A QALY is defined as 
a year lived in full health and, therefore, QALYs are estimated by multiplying the 
length of life by the utility, or the health-related quality of life6. The terms utility 
and health-related quality of life are not interchangeable. Utilities must be elicited 
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under uncertainty, i.e. using standard gamble methods, while many instruments 
measuring health-related quality of life rely on other methods6. The terms are, 
however, frequently used as if they were interchangeable and the papers in 
Appendices A, B1, C, D2, and F are no exception. As economic evaluations, which 
measure health outcomes in terms of QALYs, are frequently referred to as cost-
utility analyses, in the chapters to come the term utility will be used. As QALYs 
capture both effects and side-effects of healthcare interventions on both life 
expectancy and quality of life, it provides a generic measure of health for economic 
evaluations6. As such, comparison across interventions and disease-areas becomes 
possible if health is measured in QALYs. This makes cost-utility analysis an 
appealing approach to assess the cost-effectiveness of new technologies in 
Denmark. The notion that cost-utility analysis should be the preferred type of 
economic evaluation in Denmark was also raised in a recent report containing ten 
solutions for the fiscal challenges of the Danish healthcare system: 
“… in many respects it would be absurd to think in terms of a cost
benefit ratio. The relevant approach would be a costutility approach 
based on quality adjusted life years.”  
(Pedersen et al. 2011)8 
 
The calculation of QALYs in economic evaluations requires good utility estimates 
obtained from generic questionnaires with a preference-based valuation of health 
states6. If the Danish guideline for economic evaluations is to recommend the use of 
QALYs as the preferred outcome-measure, a practical question arises: how should 
utility be estimated? 
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1.4. MEASURING UTILITY FOR ECONOMIC EVALUATIONS IN 
DENMARK  
In order for the Danish healthcare system to compare results between cost-utility 
analyses, it is essential to use the same instrument for estimating patients’ utility. 
This is referred to as setting the ’reference case’ for a generic preference-based 
instrument by NICE12. Choosing the reference case instrument requires 
considerations about validity across different patient groups, reliability, ease of 
administration, and popularity abroad. Examples of such generic preference-based 
instruments would be the EuroQol 5 dimensions of health questionnaire (EQ-5D)13, 
the Short-Form 6 dimensions of health questionnaire, the 15 dimensions of health 
questionnaire, The Health Utilities Index questionnaires, and many more. The three 
level version of the EQ-5D questionnaire (EQ-5D-3L) contains the following five 
dimensions at three levels of severity: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. The answers to the five questions of the 
EQ-5D, the EQ-5D-3L profile, are converted into the EQ-5D index14, which will be 
referred to as a utility value in the present thesis. This is done by using weights 
from a value set (previously referred to as a ‘tariff’14,15). The weights are obtained 
by elicitation of health preferences through a time trade-off (TTO) exercise in a 
large sample of the general population. While elicitation methods are a highly 
relevant topic when discussing how to measure utility in economic evaluations, it is 
beyond the scope of the present thesis and will therefore not be addressed any 
further.  
A five level version of the EQ-5D questionnaire (EQ-5D-5L)  is also 
available16. However, the value set for the five level version is currently a crosswalk 
from the three level value set17, and the three level version, therefore, remains the 
most widely used. Hence, when referring to the EQ-5D in this thesis the 
questionnaire in question is the EQ-5D-3L. 
CHAPTER 1. INTRODUCTION 
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Currently there are Danish value sets for the EQ-5D and 15D and one of 
these might therefore be considered as the preferred instrument18,19. There are two 
important cases to be made regarding the choice between the 15D and the EQ-5D: 
1) The EQ-5D preference weights were elicited using TTO19, i.e. a choice-based 
method representing social value15, while the 15D preference weights were obtained 
using a non-choice-based method of preference elicitation18, and 2) the EQ-5D is 
more frequently used on an international level20,21. The latter issue becomes 
important if national utility data for a particular health state cannot be found and 
must be valued using the results from foreign studies. Hence, it would be preferable 
to use the same instrument as the majority of values from other instruments are not 
considered comparable6,11. The main arguments against using the EQ-5D would 
include: concerns about its generic nature22, concerns about its discriminative 
ability, and methodological arguments for using standard gamble for preference-
elicitation rather than TTO. Other instruments might have a larger discriminative 
ability than the EQ-5D and be valid over a larger range of conditions, i.e. truly 
generic, but none has currently found as wide an application and acceptance as the 
EQ-5D.  
Throughout this thesis it will, therefore, be assumed that in an updated 
Danish guideline, the reference-case for economic evaluations would be a cost-
utility analysis using the EQ-5D to measure utilities. Therefore, optimal utility 
estimates for these cost-utility analyses would require individual patient-level data 
(IPD) on EQ-5D, when treatment options are compared in clinical trials. 
Availability of such IPD would allow the national value set to be applied and, 
hereby, the cost-effectiveness results would be a reflection of national preferences 
for health. Such ideal conditions for estimating utilities are, however, not always 
present. Analysts may face situations where IPD on EQ-5D profiles are unavailable, 
but foreign utilities, or other measures of health, are available. The remainder of the 
thesis will therefore address how to obtain optimal utility measures under ideal and 
non-ideal conditions. The hypothesis is that utility estimates obtained using non-
standardized methods will bias the cost-effectiveness result, i.e. the results will not 
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reflect the national preferences for health, while standardization of the methodology 
will provide unbiased results.  
 
1.5. DEFINING THE RESEARCH QUESTION  
As explained above, there are several arguments for performing cost-utility 
analyses to assess the cost-effectiveness of new health technologies in Denmark. 
Likewise, there are several arguments for using the EQ-5D as the reference case 
instrument for measuring utility for QALY calculations. Assuming that the Danish 
Health and Medicines Authority will update the national guideline for economic 
evaluations to include a preference for cost-utility analyses, and utility measures 
from the EQ-5D, the research question is:  
HOW CAN AVAILABLE DATA BE USED TO PROCURE OPTIMAL UTILITY ESTIMATES FOR 
THE CALCULATION OF QUALITY ADJUSTED LIFE-YEARS IN THE ASSESSMENT OF COST-
EFFECTIVENESS OF NEW HEALTHCARE INTERVENTIONS? 
Calculation of QALYs under non-ideal conditions is generally considered 
technically challenging  and, therefore, NICE recently funded four technical support 
documents23–26 on this matter to compliment the NICE “guide to the methods of 
technology appraisal”12. 
   
1.5.1. DELIMITATION OF THE RESEARCH QUESTION 
Several other subjects would be equally relevant to address. Examples of such 
topics might include discussions about: the preferred perspective of the economic 
evaluations submitted to the Danish Health and Medicines Authorities, whether the 
EQ-5D should be the preferred instrument, how to elicit preference-weights, and 
what the opportunity cost might be in terms of cost per QALY. These issues will 
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not be addressed in the present work. Instead, the NICE reference-case will be 
applied to hold all other matters equal12. Hence, the present thesis will only 
elaborate on how to obtain optimal utility estimates for Danish cost-utility analyses. 
 
1.6. READING INSTRUCTIONS  
The thesis is meant as a helpful tool in the process of updating the Danish national 
guidelines for economic evaluations. The intention with this thesis is to exemplify 
why it is important to use standardized methods for estimating utility, when health 
outcomes are measured in terms of QALYs.   
As mentioned in the beginning of the introduction, this thesis is a 
compilation of methodological considerations, which arose when performing the 
three economic evaluations presented in Appendices A, B1, and F. These 
methodological considerations are summarized in Chapter 2-5. These chapters 
generally follow the same structure:  
X.1  A brief introduction to the chapter will explain why you (a reader assumed 
to be a health economist working with economic evaluations) should care 
about the content of that chapter and which papers from the appendices are 
relevant to that specific chapter.  
X.2 Then a brief introduction to the condition and the interventions 
investigated in the cost-utility analysis will follow. Here, the reader is 
encouraged to pause from reading the thesis and read the paper(s) relevant 
to the chapter, before continuing with the section named “The 
comparison”.  
X.3 Includes an exemplification of why it is important to use standardized 
methods to ensure that the results of one Danish economic evaluation can 
be compared to another.    
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X.4 The lessons learned from considering the methodological issues, which 
arose when performing the economic evaluations, are summarized in a 
preliminary conclusion. 
The preliminary conclusions are subsequently used to provide some 
recommendations for estimating health outcomes in terms of QALYs in economic 
evaluations conducted from the perspective of the Danish healthcare system.  
Each of the papers presented in Appendices A-F1–3 should be viewed as 
independent pieces of work. As such, the first table in a new paper will be named 
Table 1. The details of reference number 1 in a paper cannot be found in the 
literature list of the thesis, but must be found in the reference list of that paper. 
Likewise, at the first use of an abbreviation in a paper, the abbreviation is spelled 
out; however, it cannot be found in the glossary of the thesis.  
Appendix G contains declarations of authors’ contributions. These are 
mandatory to include when submitting a thesis, which contains articles with 
multiple authors at the Faculty of Social Sciences at Aalborg University.  
Enjoy!  
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CHAPTER 2. THE MOTIVATIONAL 
CASE 
2.1. AN INTRODUCTION TO THE CASE 
The aim of Chapter 2 is to familiarize the reader with the issues of economic 
evaluations valuing health outcomes in terms of QALYs under non-ideal 
circumstances. Section 2.3 exemplifies how much the results of two economic 
evaluations may deviate when non-standardized methods are used.  
This chapter will clarify why the remaining chapters of the thesis will 
discuss how methods, for measuring utility for economic evaluations, could be 
standardized in Denmark.   
 
2.2. THE CONDITION AND THE INTERVENTIONS 
A frequent type of cardiovascular disease is arteriosclerosis of the coronary arteries. 
This is a chronic disease which is characterized by abnormal thickening and 
hardening of the arteries that supply the heart with nutrients and oxygen27. While 
arteriosclerosis is a normal part of the ageing process, it is worsened by genetic 
predisposition, smoking, hypertension, diabetes, hypercholesterolemia, and a 
sedentary lifestyle28. As coronary arteriosclerosis develops, patients’ risk of angina, 
myocardial infarction, and mortality increases. Treatment of the condition involves 
management of risk factors through lifestyle changes and medicine and, in later 
stages, percutaneous coronary intervention or coronary artery bypass grafting 
(CABG). CABG is the preferred treatment for multi-vessel coronary artery 
disease29. CABG is a surgical treatment for coronary artery disease involving 
opening of the chest wall to allow access to the heart, see Figure 2-1. 
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Figure 2-1: Incision in the chest to obtain access to the heart. On the lefthand side a 
sternotomy - on the righthand side the minimally invasive direct coronary artery bypass. 
Illustration from30. 
 
When access is obtained, the surgical team may choose to bypass the blocked 
coronary arteries, to allow oxygen and nutrients to reach the affected heart muscles, 
by reattaching the patient’s left and right internal mammary arteries to the coronary 
circulation below the blockage, or to use an arterial/venous conduit31. The radial 
artery is used as a conduit in a mere 5.5% of bypass procedures32.  
In the majority of patients, the left internal mammary artery is connected to 
the left anterior descending coronary artery, while saphenous vein grafts are used to 
connect, or graft, healthy arteries to the remaining blocked coronary arteries, see 
Figure 2-2.  
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Figure 2-2: Triple bypass of the coronary blood flow using the left internal mammary artery 
to the left anterior descending coronary artery and two venous grafts as conduits. 
Illustration from33. 
Because the greater saphenous vein is still frequently used as a conduit, the manner 
in which it is obtained receives a lot of attention. Previously, this process involved 
harvesting the vein using an open vein harvesting (OVH) technique, with a single 
continuous skin incision. However, today the majority of vein harvesting 
procedures are performed using an endoscopic vein harvesting (EVH) technique3,34–
36
. The two economic evaluations being compared in the following section have 
both investigated the short-term cost-effectiveness of EVH compared to OVH for 
CABG37,38.  
 
2.3. THE COMPARISON   
Because both studies estimated the cost-effectiveness in terms of cost per QALY 
under non-ideal circumstances, these offer a great motivational case. The two 
studies applied slightly different methodologies; the first study generated a decision 
analytic model aimed at calculating cost per QALY38, whereas the second study 
PUTTING THE ‘Q’ IN QALY IN COST-UTILITY ANALYSES 
14 
was a piggy-back cost-effectiveness analysis of a randomized controlled trial, 
which calculated both cost per purulent infection avoided and cost per QALY37. 
The studies considered slightly different types of resource consumption and this 
resulted in two quite different estimates of mean incremental costs, see Table 2-1.  
 
Table 2-1: Results of two economic evaluations comparing endoscopic vein harvesting to 
open vein harvesting for patients undergoing coronary artery bypass grafting37,38. 
Analysis Incremental  
Cost*  
 
($ USD) 
Incremental 
Effect* 
 
(QALYs) 
ICER 
 
 
($/QALY) 
Probability 
of being 
cost-
effective at 
$50,000 per 
QALY  
Oddershede et al.37 $217.14 0.00273 79,391 >1% 
Rao et al.38 $458.74 0.0231 19,859 95.6% 
ICER – incremental cost-effectiveness ratio; QALY – quality adjusted life-years. USD – 
United States Dollar. * Increments were calculated as endoscopic vein harvesting minus 
open vein harvesting. 
  
Both studies shared a problem – they were unable to identify preference-based 
measures of health for the EVH group. Therefore, both studies estimated the utility 
gain from evidence that EVH decreases pain intensity and increases postoperative 
mobility, compared to OVH. As this was done based on the analysts and clinicians 
judgments, it is not surprising that they did not arrive at the same estimate. It is, 
however, very surprising how different the estimates were. Oddershede et al.37 
arrived at an estimate, which was almost a tenth of Rao et al.38. Needless to say, 
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such a difference may have a massive impact on the cost-effectiveness results and 
cause analysts to arrive at different decisions, which is exactly what happened in 
this case: Rao et al.38 estimated EVH to be cost-effective, while Oddershede et al.37 
did not.  
 
2.4. PRELIMINARY CONCLUSION 
The reservation towards QALY estimates based on analysts’ and clinicians’ 
judgment, i.e. judgment mapping, can easily be summarized:  
“The main criticism of this approach is its arbitrariness.” 
(Brazier et al. 2007)11 
Through this motivational example, it is evident that standardized methods must be 
applied if the study is intended to inform a decision about allocation of scarce 
resources. Furthermore, the motivational case supports the first part of the 
hypothesis: cost-effectiveness results can be biased if non-standardized methods are 
used to calculate QALYs. The remaining chapters will, therefore, focus on how to 
avoid biased QALY estimates through the use of standardized methods.   
In the motivational case, the QALY calculations could have been 
standardized by “mapping” based on the statistical association between the 
measures of health at hand, and the EQ-5D39. 0 will return to the matter of how this 
non-ideal situation could be handled, whereas the following Chapter will exemplify 
why it is ideal to have IPD on EQ-5D profiles. 
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CHAPTER 3. WHEN PATIENT-LEVEL 
EQ-5D DATA ARE AVAILABLE  
3.1. AN INTRODUCTION TO THE CASE 
The case presented in Chapter 2 served to illustrate how health outcomes, measured 
in QALYs, are difficult to value in the absence of utility data in the literature. The 
case put forward in the present chapter serves to show how easily an estimate of 
health outcomes measured in QALYs can be obtained when IPD of EQ-5D profiles 
are available. The economic evaluation presented in this chapter was performed 
during a stay abroad at the Centre for Health Economics (University of York, UK) 
and as such it was conducted from the perspective of the UK NHS and Personal 
Social Services. The comparison in section 3.3 will show how IPD used to obtain 
the UK estimate of incremental QALYs may be reused to obtain a Danish estimate.  
 
3.2. THE CONDITION AND THE INTERVENTIONS 
Human immunodeficiency virus (HIV-1) is an infectious disease. The virus leads to 
depletion of different types of cells of the immune system, specifically the CD4+ T 
cells. As the number of CD4+ T cells decline, the immune system fails and the 
body becomes increasingly susceptible to opportunistic infections. Over time, these 
opportunistic infections become life-threatening and may be accompanied by 
development of cancers40.  
The current standard-of-care treatment for patients living with HIV-1 is 
combination antiretroviral therapy (ART), usually consisting of three drugs: two 
nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse 
transcriptase inhibitor or a protease inhibitor41,42. An increasing pool of evidence 
suggests that protease inhibitor monotherapy (PIM) may be sufficient to maintain 
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complete virological suppression for patients who have achieved sustained 
virological suppression43. A recent trial randomised 587 HIV-1 infected patients 
who had achieved sustained virological suppression to a strategy of Protease 
Inhibitor monotherapy Versus Ongoing Triple-therapy (the PIVOT trial) and found 
PIM non-inferior to ongoing triple-therapy (OTT) in terms of preserving future 
drug options44. Likewise, the PIM strategy was shown to be no different than OTT 
in terms of safety and could, therefore, be considered a treatment option in the long-
term management of HIV-1 infected patients44. While the PIM strategy might 
require a stricter regimen of follow-up than the OTT, it is likely to reduce ART 
drug costs substantially. If the PIM strategy is also comparable to OTT in terms of 
QALYs gained this may make PIM cost-effective compared to OTT. However, the 
cost-effectiveness of PIM is unknown43. The objective of the case-study presented 
in Appendix A was to investigate the cost-effectiveness of a strategy of switching to 
PIM compared to continuing OTT in HIV-1 infected patients. 
A detailed description of the methods used to perform the economic 
evaluation can be found in the methods section of the paper in Appendix A. 
 
3.3. THE COMPARISON 
The base-case in the economic evaluation was a within-trial analysis. IPD on 
consumption of health care resources and ART use were used to calculate costs. 
QALY calculations were based on IPD of EQ-5D profiles. The EQ-5D profiles 
were converted into utilities using the UK value set45. The base-case analysis 
handled missing values of costs and utilities by means of multiple imputation, and, 
as a supplementary sensitivity analysis, a complete-case analysis was conducted. 
Regression methods were used to adjust costs and QALYs for baseline covariates in 
both the base-case analysis and the complete-case analysis. Results are summarized 
in Table 3-1. 
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Table 3-1: Results from Appendix A (value set from United Kingdom applied to the EQ-5D 
profiles) 
Analysis Incremental* 
cost  
(£) 
Incremental* 
effect 
(QALY)  
ICER 
 
(£/QALY) 
Probability of 
being cost-
effective at 
£20,000 per 
QALY  
Base-case -£6,424.11 a 0.0051 a Dominant 100%  
Complete-case -£6,417.15 b -0.0227 c 282,641 ** 100%  
EQ-5D – EuroQol five dimensions of health questionnaire; ICER – incremental cost-
effectiveness ratio; m – number of imputations; n – number of patients; OTT – ongoing triple 
therapy; PIM - protease inhibitor monotherapy; QALY – quality adjusted life-years; * 
Increments were calculated as PIM minus OTT; **ICER in southwest quadrant of the cost-
effectiveness plane; aPIM (n=296, m=20) & OTT (n=291, m=20); bPIM (n=266, m=0) & 
OTT (n=254, m=0); cPIM (n=142, m=0) & OTT (n=130, m=0);  
 
The incremental QALYs presented in Table 3-1 reflect the UK valuation of 
health states, in line with current UK guidelines for cost-effectiveness analysis12. If 
this economic evaluation had been conducted from the perspective of the Danish 
health care system it would be reasonable to apply the Danish value set. When the 
Danish value set is applied to the EQ-5D profiles the mean utility becomes a 
reflection of how the Danish general population values health, and as an extension, 
how the general population values a particular health gain. When IPD, of EQ-5D 
profiles, are readily available to the analyst another value set can easily be applied. 
The cost-effectiveness results obtained from using the Danish value set are shown 
in Table 3-2.  
It is striking that the present study found the incremental QALY in the UK 
base-case to be 1.5 times larger than the Danish base-case. This is in agreement 
with what a Swedish study found when applying the Danish and the UK value sets 
to the same IPD in a group of rheumatoid arthritis patients46. 
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Table 3-2: Results when applying value set from Denmark to the EQ-5D profiles from 
Appendix A. 
Analysis Incremental* 
cost  
(£) 
Incremental* 
effect 
(QALY)  
ICER 
 
(£/QALY) 
Probability of 
being cost-
effective at 
£20,000 per 
QALY 
Base-case -£6,420.60 a 0.0034 a Dominant 100%  
Complete-case -£6,417.15 b -0.0220 c 292,035 ** 100%  
EQ-5D – EuroQol five dimensions of health questionnaire; ICER – incremental cost-
effectiveness ratio; m – number of imputations; n – number of patients; OTT – ongoing triple 
therapy; PIM - protease inhibitor monotherapy; QALY – quality adjusted life-years; * 
Increments were calculated as PIM minus OTT; **ICER in southwest quadrant of the cost-
effectiveness plane; aPIM (n=296, m=20) & OTT (n=291, m=20); bPIM (n=266, m=0) & 
OTT (n=254, m=0); cPIM (n=142, m=0) & OTT (n=130, m=0).  
 
When comparing the UK base-case analysis of incremental QALYs to the Danish 
base-case analysis the interpretation requires caution. The reason is that the missing 
utility values were handled by two separate imputation-models and differences in 
the incremental QALYs could, therefore, be attributable to the multiple imputation 
of missing values, rather than to differences in valuation between countries. As 
such, the difference between the incremental QALY in the UK and Danish 
complete-case may be the most appropriate way to exemplify how a nation’s 
valuation of health affects the results of an economic evaluation. The difference in 
the incremental QALYs can seem minute in the present case, but this is merely 
because PIM is very cost-saving compared to OTT. Had the incremental cost been a 
tenth of what it is in the present case, the implications of a difference in the 
incremental QALY would be much greater.  
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3.4. PRELIMINARY CONCLUSION 
As such, it is important to use the Danish value set in economic evaluations 
conducted from the perspective of the Danish healthcare system whenever IPD on 
EQ-5D profiles are available. An unbiased reflection of the Danish preferences for 
health can only be obtained by using the national value set to estimate the 
incremental effectiveness. Consequently, it is easy to obtain unbiased QALY 
estimates when IPD on EQ-5D profiles are available but, unfortunately, this is not 
always the case. 
 
  
PUTTING THE ‘Q’ IN QALY IN COST-UTILITY ANALYSES 
22 
  
CHAPTER 4. WHEN PATIENT-LEVEL EQ-5D DATA ARE UNAVAILABLE BUT FOREIGN EQ-5D UTILITIES ARE 
AVAILABLE 
23 
CHAPTER 4. WHEN PATIENT-LEVEL 
EQ-5D DATA ARE UNAVAILABLE BUT 
FOREIGN EQ-5D UTILITIES ARE 
AVAILABLE 
4.1. AN INTRODUCTION TO THE CASE 
Economic evaluations are only occasionally used to inform decision making in the 
Danish healthcare system and the clinical trials, therefore, rarely collect IPD on EQ-
5D profiles. However, such data may have been collected in foreign studies. In 0 it 
was explained why the optimal solution for a Danish economic evaluation would be 
to use the IPD on EQ-5D profiles from a foreign study and apply the Danish value 
set to these data. However, it may not always be possible for analysts to obtain IPD 
from foreign studies. In such situations the mean utility of the EQ-5D, valued by a 
foreign value set, will have to be used.  
Evidence does, however, suggest that foreign utilities may not be 
transferable to a Danish setting15,46–54. Analysts are advised to adjust utilities before 
applying them in economic evaluations47. However, if IPD on EQ-5D profiles 
cannot be obtained there are no published methods for adjusting mean utilities 
across countries. Therefore, a novel method for adjusting mean utilities of the EQ-
5D between countries was developed, see Appendix C. In section 4.3 we investigate 
the importance of performing adjustments by using the results of the economic 
evaluation presented in Appendix B1.  
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4.2. THE CONDITION AND THE INTERVENTIONS 
The normal heart rhythm is generated in the sinus node in the atrium of the heart. 
From there, the signal travels through the heart while causing the atriums and 
ventricles of the heart to contract at an appropriate pace27. In patients suffering from 
arrhythmias, the conduction system is disturbed. This causes irregular rhythms 
and/or decreased pumping ability which can lead to an array of health issues 
ranging from unpleasant heart palpitations, through dizziness to stroke, heart 
failure, and death27.     
In patients suffering from the arrhythmia called sick sinus syndrome, 
bradycardia (a slow heart rate) should be treated with either a single-lead atrial 
pacemaker (AAIR) or a dual-chamber pacemaker (DDDR). In sick sinus syndrome, 
cardiac pacing is mainly used to obtain relief from the symptoms55, and to avoid the 
development of systemic thromboembolism56. Following the publication of the 
Danish multicenter randomized trial on AAIR versus DDDR in sick sinus syndrome 
(the DANPACE trial)57, DDDR pacing has been recommended as the standard 
treatment option55. However, this recommendation was controversial from a health 
economic point of view. Although DDDR pacing reduces the costs of 
reoperations57, the DDDR device costs are higher than AAIR device costs58. 
Furthermore, no studies had reported a comparison of the resource consumption for 
AAIR pacing vs. DDDR pacing. To aid decision-making, an economic evaluation 
was developed using pooled IPD from three randomized controlled trials, 
comparing DDDR pacing with AAIR pacing for sick sinus syndrome patients with 
preserved atrioventricular conduction. The full study can be found in Appendix B1. 
 
4.3. THE COMPARISION 
The economic evaluation in Appendix B1 used UK utilities of the EQ-5D for the 
health states in the Markov model. In the present section, the published results are 
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compared to the results, which would be obtained if the utilities had been adjusted 
to represent the Danish preference for health using the method in Appendix C. The 
method presented in Appendix C was developed to adjust German or Dutch utilities 
to the UK setting. By applying the Danish19 and the UK45 value sets to the same 
estimation dataset and plotting them against each other it is possible to obtain a 
formula for adjusting UK utilities of the EQ-5D to the Danish setting: 
Danish utility = 0.7831 * UK utility + 0.2057 
The impact of using foreign utilities in the economic evaluation in Appendix B is 
assessed by inserting the Danish mean utilities instead. The results of the 
comparison are presented in Table 4-1.  
 
Table 4-1: Cost-effectiveness results from Appendix B1 for Risk Group 2 in the adjusted 
pooled approach using UK utilities and utilities adjusted to the Danish setting.   
Analysis Incremental* 
cost  
(£) 
Incremental* 
effect 
(QALY)  
ICER 
 
(£/QALY) 
Probability of 
being cost-
effective at 
£20,000 per 
QALY  
UK utilities 
 
-£3,855.65 -0.170 22,709 ** 50.7%  
UK utilities 
adjusted to a 
Danish setting 
-£3,855.65 -0.179  21,504 ** 50.6%  
ICER – incremental cost-effectiveness ratio; QALY – quality adjusted life-year; UK – United 
Kingdom; * Increments were calculated as dual-chamber pacing minus single-lead atrial 
pacemaker; **ICER in southwest quadrant of the cost-effectiveness plane; 
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In Table 4-1 it is seen that UK utilities adjusted to Danish preferences for 
health yielded a slightly different result than originally published1. The original 
model used UK utilities from a catalogue of utilities for chronic conditions59 and 
found an incremental QALY of -0.170. This was done under the assumption that 
the cultural similarities between Denmark and the UK made it possible to use mean 
UK utilities when Danish utilities were not available49. While Denmark and the UK 
may have comparable cultures, their value sets are very different. In fact, the 
utilities obtained from the Danish value set is more comparable to those obtained 
from the US value set, than to utilities from the UK value set, see Figure 4-1. 
 
 
Figure 4-1: Comparison of the time trade-off value sets for Denmark, the United Kingdom 
(UK) and the United States (US). The graphs show the utility values obtained when applying 
the value sets to the 243 health states of the three leveled version of the EuroQol five 
dimensions of health questionnaire (EQ-5D-3L). Health states are ordered so that the x-axis 
runs from the least severe health state (11111) to the most severe health state in the Danish 
value set (33333). 
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The red line, the US utility values, runs much closer to the black line, the Danish 
utility values, than the blue line, the UK utility values. As such, US utilities for 
chronic conditions60,61 are a closer reflection of Danish preference for health, than 
UK utilities59, and could have been applied instead. Or better yet: Danish utilities 
for chronic conditions, which are being developed62. 
 
4.4. PRELIMINARY CONCLUSION 
It is not all that surprising that application of foreign utilities in a Danish decision 
analytic model will yield different results than one would have obtained using 
national utility values. This was shown in section 3.3 by applying UK and Danish 
value sets to the same IPD for a HIV trial and the same has been shown in a 
rheumatoid arthritis trial by others46. 
What is new and interesting is that it is possible to adjust foreign mean 
utilities of the EQ-5D to national preferences for health. The paper presented in 
Appendix C showed a novel method for this. A method, which seems to be working 
but also a method that needs further development before it can become a part of 
routine practice when transferring foreign utilities. The method could benefit from 
being developed using a larger number of mean index scores with a larger range 
than the estimation dataset used in Appendix C.  
Adjusting foreign utilities to make them reflect national preferences for 
health has great potential. It will enable countries, such as Denmark, which 
frequently face difficulties in finding national utility estimates from the relevant 
patient population, to use foreign values more readily. Furthermore, the synthesis of 
EQ-5D utilities for NICE submissions could potentially include more estimates as 
the foreign estimates could be adjusted to reflect UK preferences for health. This 
would increase precision, as NICE recommends pooling the relevant estimates in 
the same manner as aggregate clinical data25. 
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CHAPTER 5. WHEN PATIENT-LEVEL 
AND AGGREGATE EQ-5D DATA ARE 
UNAVAILABLE – BUT OTHER 
MEASURES OF HEALTH ARE 
AVAILABLE 
5.1. AN INTRODUCTION TO THE CASES 
Economic evaluations inform decision makers on how to allocate scarce resources 
to obtain the maximum amount of value-for-money. Therefore, a shared measure of 
‘value’ (QALYs) must be used in all economic evaluations to facilitate comparison 
between all interventions for all conditions. As an extension of this argument, the 
estimates of utility must be obtained using a single shared instrument. However: 
“Key trials or studies often do not use one of the generic preference-
based measures, but have used a non-preference-based health or quality 
of life measure. This situation is far from ideal, but surprisingly 
common. ”  
(Brazier et al. 2007)11 
Because utility data from the preferred instrument, assumed to be EQ-5D in this 
thesis, is not always accessible, a shared standard for handling this would be useful. 
Section 5.1.1 will address which methods could be used to handle the situation 
where IPD on EQ-5D profiles is not available. In section 5.2 the results of non-
standardized methods will be compared to the method, which may be used when 
IPD on EQ-5D profiles are not available: mapping.  
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5.1.1. MAPPING AND OTHER WAYS OF OBTAINING UTILITY 
ESTIMATES IN THE ABSENCE OF EQ-5D DATA 
Different approaches could be suggested: utility values obtained from other 
preference-based instruments could be used, a vignette could be developed and 
valued, additional EQ-5D data could be collected, or non-preference-based 
measures of health could be mapped to the EQ-5D. The process of mapping can 
best be explained in the following way: 
“Mapping is the development and use of an algorithm (or algorithms) to 
predict health-state utility values using data on other indicators or 
measures of health. The algorithm can be applied to data from clinical 
trials, other studies or economic models containing the source predictive 
measure(s) to predict utility values…”  
(Longworth et al. 2011)26 
Concerns could be raised with all approaches. Other preference-based measures of 
health might measure different aspects of utility, even if these are called generic 
instruments, see Figure 5-1.  
 
Figure 5-1: Utility measured by various instruments. Aspects that are measured frequently 
overlap but the extent to which these overlap may vary. 
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If different aspects are measured it makes it more probable that changes in 
overlapping dimensions with the EQ-5D are valued differently. Therefore, it 
becomes problematic to interpret the ICER obtained from an economic evaluation 
that used another generic preference-based instrument in relation to other economic 
evaluations that applied the EQ-5D.  
A concern, which is frequently raised regarding the use of vignettes, is 
whether the vignette can be constructed to reflect the clinical evidence and the 
uncertainty surrounding the outcome of the treatment. On top of this concern, 
ICERs obtained from economic evaluations using vignettes are equally difficult to 
interpret.  
Collecting additional data is always an excellent solution; however, it is 
usually also a very expensive and time-consuming solution. This leaves mapping.  
Mapping is, however, limited by the assumption that the EQ-5D covers all 
the important aspects of health covered by the non-preference-based measures of 
health. This may be the case for some non-preference-based measures of health, but 
not for others, as illustrated by the slightly overlapping circles in Figure 5-1.  
Another issue with mapping is whether a mapping-algorithm is available or feasible 
to produce11. Recently it became easier to determine the availability of appropriate 
mapping-algorithms after the launch of a database which contains readily available 
mapping-algorithms63. A mapping-algorithm could be considered appropriate if it is 
able to predict the EQ-5D utility, valued by the preferred value set, from the 
available non-preference-based measures of health. If an appropriate mapping-
algorithm can be obtained, the process of mapping has been shown to produce a 
valid estimate of the incremental QALY64, but also, to underestimate the 
uncertainty in the incremental QALY65. If the mapping-algorithm is not appropriate 
it is likely that it cannot successfully predict the EQ-5D utility66. In the presence of 
multiple mapping-algorithms it may be prudent to conduct sensitivity analyses 
investigating the importance of choice of mapping-algorithm66. However, it has 
been shown to be unimportant whether the mapping-algorithm is designed to map 
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the non-preference-based measures of health to the EQ-5D responses or directly to 
the utility value67. As such, mapping using a statistical algorithm should only be 
viewed as a second-best solution to IPD on EQ-5D profiles. 
 
5.2. THE CONDITION AND THE INTERVENTIONS 
The comparison of mapping, using a mapping-algorithm based on the statistical 
association of outcomes, to the non-standardized method of mapping based on 
clinicians or experts’ judgment (judgment mapping), is based on the condition and 
interventions presented in section 2.2. Readers are encouraged to spend a second 
refamiliarizing themselves with the interventions, if necessary.  
 
5.3. THE COMPARISON 
The comparison in 0 is divided in two. The first part (section 5.3.1) compares the 
results of a previous economic evaluation by Oddershede et al.37 to the results that 
could have been obtained if one of the two mapping-algorithms2,68, which are now 
available, had been applied to the IPD. The second part (section 5.3.2) compares the 
use of the two available mapping-algorithms on aggregate data to the results of the 
economic evaluation by Rao et al.38 who mapped aggregate data without a 
mapping-algorithm.   
 
5.3.1. MAPPING IPD USING A MAPPING-ALGORITHM VERSUS 
JUDGMENT MAPPING 
In section 2.3, the lack of a mapping-algorithm meant that the two economic 
evaluations arrived at very different estimates of the incremental QALY. Since the 
publication of these economic evaluations, two mapping-algorithms have been 
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published2,68. The mapping-algorithm presented in Appendix D2 was developed for 
the purpose of predicting the Danish EQ-5D utility value from non-preference-
based measures of health measured on visual analogue scales (VAS) for CABG 
patients. Hence, this mapping-algorithm was specifically designed for the purpose. 
The mapping-algorithm presented in Appendix D2 explained as much as 65% of the 
variability in the Danish EQ-5D utility, which is quite high compared to  mapping-
algorithms in general39. The second mapping-algorithm that has become available 
maps pain measured on a VAS to the UK EQ-5D utility in shoulder patients68. No 
other dimensions of health were included in the mapping-algorithm and, hence, it 
merely explained approximately 10% of the variation in the UK utility value. As 
such, this second mapping-algorithm serves as an example of the importance of 
using an appropriate mapping-algorithm. 
In Table 5-1 the results of the previous economic evaluation by 
Oddershede et al.37 are presented along with the results which would have been 
obtained with the two mapping-algorithms that are available now2,68. 
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Table 5-1: Cost-effectiveness results when IPD of non-preference-based measures of health 
are mapped based on judgment and based on statistical mapping-algorithms 
Analysis Incremental  
Cost*  
 
($ USD) 
 
Incremental 
Effect* 
 
(QALYs) 
 
ICER 
 
 
($/QALY) 
Probability 
of being 
cost-
effective at 
$50,000 
per QALY  
Judgment mapping of 
IPD from Oddershede 
et al.37 
$217.14 ** 0.00273 79,391 >1% 
Mapping IPD from 
Oddershede et al.37 
using mapping-
algorithm from 
Appendix D2 
$222.46 ** 0.00269 82,791 >1% 
Mapping IPD from 
Oddershede et al.37 
using mapping-
algorithm from Maund 
et al.68 
$222.46 ** 0.00120 185,693 >1% 
ICER – incremental cost-effectiveness ratio; IPD – individual patient-level data; QALY – 
quality adjusted life-year; USD – United States Dollar; * Increments were calculated as 
endoscopic vein harvesting minus open vein harvesting. ** Stata’s “set seed” function was 
not used to generate the incremental cost published in Oddershede et al.37 and the new 
bootstrap analysis, therefore, produced a slightly different mean incremental cost.  
 
It is seen that the incremental QALY estimated in the previous economic 
evaluation37 closely resembles the estimate obtained when using the mapping-
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algorithm presented in Appendix D. This is merely a coincidence. The original 
results were not mapped using a mapping-algorithm based on the statistical 
association of outcomes, but by judgment mapping, and section 2.3 clearly showed 
the variability in estimates of incremental QALYs obtained by judgment mapping. 
As such, the results presented in Table 5-1 cannot be used as an argument of the 
validity of mapping without a mapping-algorithm. However, a rather large 
difference between the estimate obtained from the mapping-algorithm presented in 
Appendix D2 and the estimate obtained using the mapping-algorithm developed by 
Maund et al.68. This stresses that mapping is a valid second-best approach only if an 
appropriate mapping-algorithm is available.  
 
5.3.2. MAPPING AGGREGATE DATA USING A MAPPING-ALGORITHM 
VERSUS JUDGMENT MAPPING   
Previous economic evaluations of EVH vs OVH for CABG have applied a short 
time-horizon37,38. In many instances, and especially for interventions in chronic 
conditions, a lifetime horizon would be more appropriate69. Especially in the case of 
EVH vs OVH the short time horizon became an issue as the long-term EVH graft 
patency was questioned in an observational study70. Although it seems evident that 
EVH is not associated with an increased mortality34, the uncertainty lingers in the 
clinical community and causes the initiation of new randomized clinical trials71,72. 
Because of the uncertainty surrounding long-term outcomes recent reviews called 
for a more rigorous cost-effectiveness analysis73,74. To be able to compare EVH to 
OVH in terms of lifetime costs and outcomes, it was necessary to conduct a 
systematic review with meta-analysis. Previous meta-analyses had defined the 
comparators (and outcomes) different from one and another, and none had used the 
definitions which we believed to be appropriate75–84. Therefore, a new meta-
analysis was conducted, see the paper in Appendix E3. The meta-analysis pooled 
data on resource consumption, long-term clinical endpoints relevant to decision 
analytic modeling, and short-term clinical endpoints to enable mapping of the short-
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term utility gain from using EVH. Based on the summary statistics from the meta-
analysis in Appendix E3, a Markov model was constructed to allow modeling of 
short-term and life-time costs and QALYs. The summary statistics of short-time 
non-preference-based measures of health, from the meta-analysis in Appendix E3, 
were mapped using the generalized least squared mapping-algorithm number two 
from Appendix D2. The methods and full results of the economic evaluation of 
lifetime costs and QALYs are presented in Appendix F. 
The present comparison is merely a comparison of how short-term 
estimates of the incremental QALY could be obtained using mapping methods. 
Three approaches could be used. Firstly, the summary statistics from the meta-
analysis, in Appendix E3, could be mapped using an appropriate mapping-
algorithm2. Secondly, the summary statistics from the meta-analysis, in Appendix 
E3, could be mapped using a mapping-algorithm68 considered inappropriate for the 
analysis in Appendix F. Thirdly, the aggregate summary data could have been 
mapped by judgment as it was in the study by Rao et al.38. The results from the 
three approaches are summarized in Table 5-2. 
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Table 5-2: Aggregate data, from the meta-analysis in Appendix E3, mapped using two 
mapping-algorithms2,68, compared to judgment mapping of aggregate data. 
Analysis Incremental 
Costs  
 
($ USD) 
Incremental 
Effect 
 
(QALYs) 
ICER 
 
 
($/QALY) 
Probability 
of being 
cost-
effective at 
$50,000 
per QALY  
Rao et al.38 $458.74 0.0231 19,859 95.6%  
Mapping aggregate 
data from the meta-
analysis in Appendix 
E3 using the mapping-
algorithm developed in 
Appendix D2  
$849.78 * 0.0048 178,866 * 17.0% 
Mapping aggregate 
data from the meta-
analysis in Appendix 
E3 using the “Model 1” 
mapping-algorithm 
from Maund et al.68 
$849.78 * 0.0029 297,601 * 10.0% 
ICER – incremental cost-effectiveness ratio; QALY – quality adjusted life-year; * The 
incremental costs were converted from Pounds Sterling (£) to US dollars (USD $) using a 
conversion rate of 1.6804 $ per £.  
 
A great variation is seen in the three estimates of incremental QALY in 
Table 5-2. The difference is largest when comparing the result which Rao et al.38 
obtained by judgment mapping, to mapping using a mapping-algorithm based on 
PUTTING THE ‘Q’ IN QALY IN COST-UTILITY ANALYSES 
38 
the statistical association of outcomes. In other words, standardized methods will 
produce more consistent results than unstandardized methods. In contrast to section 
5.3.1, the results in Table 5-2 suggest that an inappropriate mapping-algorithm is 
better than judgment mapping.   
 
5.4. PRELIMINARY CONCLUSION 
A number of valuable lessons emerges from the process of developing a mapping-
algorithm (Appendix D2), systematically reviewing and pooling the aggregate data 
(Appendix E3), and using the summary measures to estimate the life-time cost-
effectiveness of EVH (Appendix F). Firstly, the process of mapping was more 
reliable than judgment mapping, even when applying a mapping-algorithm68 
considered inappropriate for the present analysis. Secondly, it would dramatically 
increase the usability of mapping-algorithms if these were: a) developed to map 
EQ-5D responses or b) accompanied by an appendix where a number of different 
value sets had been applied to the EQ-5D responses. Thirdly, it is a time-consuming 
exercise and should only be applied if utilities of the EQ-5D cannot be obtained in 
other ways. Nonetheless, it should be viewed as the best way to handle the absence 
of IPD on EQ-5D profiles and mean utilities of the EQ-5D. A comparison between 
all interventions for all conditions can only be facilitated if a single shared 
instrument is used to measure utility. As such, it is necessary to use the reference 
case instrument, assumed to be EQ-5D in this thesis, to measure differences in 
utility, or, to predict the differences in utility using a mapping-algorithm that 
predicts utilities of the EQ-5D from other measures of health. 
Therefore, the take home message is: whenever a trial is initiated, either 
observational or randomized, IPD on EQ-5D profiles should be collected. By doing 
so, time-consuming mapping-exercises may be avoided. 
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CHAPTER 6. CONCLUSION 
The current Danish guideline for economic evaluations submitted to the Danish 
Health and Medicines Authorities do not take a position towards the preferred type 
of economic evaluation. In Section 1.2 the two main issues with this was identified 
as: firstly, incomparability of economic evaluations, and secondly, choosing an 
outcome-measure that captures both the effects and side effects of treatments. 
It was argued that updating the Danish guideline to include a stated 
preference for cost-utility analyses would solve these issues, if the utility estimates, 
used in the analyses, were obtained by the means of standardized methods. 
Therefore, the present thesis investigated, through methodological studies and case-
studies, how the available data could be used to procure optimal utility estimates for 
QALY calculations.   
The results indicate that if economic evaluations are to be used to inform 
decision makers of the cost-effectiveness of new technologies, it is not only 
necessary to have a stated preference for cost-utility analysis, but also to include 
thorough instructions for estimating utility. The present thesis showed that 
estimates of incremental QALYs are unlikely to be an unbiased reflection of 
national preferences for health if standardized methods for estimating utility have 
not been applied. 
First of all, it should be noted that an update of the Danish guideline for 
economic evaluations is long overdue! Several advances have been made, within 
health economics, since 1998 and the national guideline should be updated to 
reflect this.  
If the Danish Health and Medicines Authorities choose to update the 
national guideline for economic evaluations to include a preference for cost-utility 
analyses, they should include instructions on estimating utilities. The key to making 
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the results comparable and relevant to the Danish setting is to request that 
standardized methods be applied in all evaluations of new technologies. Amongst 
other things, it would be important to standardize which generic preference-based 
instrument to use, how to apply foreign utilities in Danish economic evaluations, 
and how it should be handled if utility data are not available to the analyst. The 
present thesis suggested standardized methods for handling the latter two in the 
papers presented in Appendix C and Appendix D.  
While the conclusion of this thesis addresses which initiatives the Danish 
Health and Medicines Authorities might take to improve the usefulness of the 
economic evaluations submitted to them, the advice also has a more universal ring 
to it. All economic evaluations may benefit from applying standardized methods 
such as e.g. those developed and advocated for in this thesis.  
 
 
 
 
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Resources are scare and healthcare systems must, therefore, prioritize which new 
technologies should be funded, and which should be rejected. To aid decision 
makers in their choice, economic evaluations can be conducted to assess the 
cost-effectiveness of the new technologies. 
The present thesis argues that two problems could be solved by updating the 
Danish guideline for economic evaluations to include a stated preference for 
measuring effectiveness in terms of quality adjusted life-years (QALYs). Firstly, 
it would be possible to compare the cost-effectiveness of new technologies across 
conditions. Secondly, it would make it possible to capture both effects and side 
effects of new technologies in a single outcome measure. Therefore, the pres-
ent thesis explores how to procure optimal estimates of quality of life, i.e. util-
ity, for QALY calculations in different situations, depending on which data are 
available.
Using the methodological papers and economic evaluations conducted during 
the PhD project; the thesis exemplifies why it is important to use standardized 
methods when calculating QALYs in economic evaluations. 
The thesis recommends that a shared measure of health, QALYs, is used in order 
to make the results of the economic evaluations submitted to the Danish Health 
and Medicines Authorities more comparable across conditions and interventions. 
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